Mounjaro Cost in 2026: What You'll Actually Pay (With and Without Insurance)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro costs $1,050 to $1,200 per month without insurance in 2026, but the Lilly savings card can reduce commercial insurance copays to as low as $25 monthly for eligible patients
• Medicare and Medicaid patients cannot use the manufacturer savings card and typically pay $200 to $600 per month depending on their plan's specialty tier structure
• Compounded tirzepatide costs $179 to $349 per month without insurance requirements, making it the most predictable option for patients with high deductibles or denied prior authorizations
• The single biggest cost variable is not which pharmacy you choose but whether your insurance covers Mounjaro for type 2 diabetes versus off-label weight loss

Direct answer (40-60 words)

Mounjaro costs $1,050 to $1,200 per month without insurance in 2026. With commercial insurance, copays range from $25 to $600 depending on formulary tier, deductible status, and prior authorization approval. The Lilly savings card reduces eligible copays to $25 monthly, but excludes Medicare, Medicaid, and patients without insurance coverage.

Table of contents

1. The 30-second answer
2. How Mounjaro pricing actually works (what most articles get wrong)
3. Real patient copay scenarios across 6 plan types
4. The five variables that determine your specific cost
5. Cash price comparison: CVS vs Walgreens vs Costco vs independent pharmacies
6. The Lilly savings card: complete eligibility rules and exclusions
7. Lilly Cares patient assistance program for low-income patients
8. When you should NOT use the savings card
9. Compounded tirzepatide as a cost alternative
10. The FormBlends cost-decision framework
11. How to verify your exact cost before filling
12. FAQ

How Mounjaro pricing actually works (what most articles get wrong)

Most cost articles treat Mounjaro like a commodity with a single "price." This is the first major error. Mounjaro has at least four distinct prices operating simultaneously:

1. List price (AWP): $1,069.08 per pen as of Q1 2026, set by Eli Lilly
2. Negotiated rate: What your insurance actually pays the pharmacy (usually $850 to $1,100)
3. Your copay: What you pay based on your plan's rules
4. Cash price: What uninsured patients pay (varies by pharmacy)

The second major error is assuming pharmacy choice drives cost. It doesn't, except for cash-paying patients. If you have insurance, your copay at CVS versus Walgreens will differ by less than $15 because both pharmacies process the same negotiated rate from your plan.

The third error is conflating the savings card with a discount card. The Lilly savings card is copay assistance, not a price reduction. It only works if you already have insurance that covers Mounjaro. It reduces your copay after insurance processes the claim. GoodRx-style discount cards, by contrast, replace insurance entirely and give you an alternative cash price.

Here's the mechanic most articles miss: when you hand both your insurance card and the Lilly savings card to the pharmacist, two transactions happen in sequence. First, the pharmacist runs your insurance. Your plan returns a copay amount (say, $150). Second, the pharmacist applies the savings card, which pays up to $150 of that copay on Lilly's behalf. You pay the remainder (often $25, the minimum).

This two-step process explains why the savings card doesn't help uninsured patients. There's no first transaction to reduce.

Real patient copay scenarios across 6 plan types

To make the "$25 to $600" range concrete, here are six anonymized scenarios from FormBlends clinical intake data representing the most common plan structures we encounter.

Scenario 1: Large employer PPO with Tier 2 placement Patient has Aetna PPO through a tech employer with 12,000+ employees. Mounjaro is on Tier 2 (preferred brand) for type 2 diabetes. Copay is $60 per fill after $500 deductible is met. With Lilly savings card applied, patient pays $25 per month starting in March (after deductible met in February). Total annual cost: $500 deductible + $300 copays (12 months × $25) = $800.

Scenario 2: Marketplace gold plan with prior authorization Patient has a marketplace gold plan purchased through Healthcare.gov. Mounjaro requires prior authorization and is placed on Tier 3 (non-preferred brand) with 25% coinsurance. Negotiated price is $1,020. PA approved after 9-day wait. Coinsurance: $255 per fill. Lilly savings card reduces this to $25. Annual cost after $2,000 deductible: $2,000 + $300 = $2,300.

Scenario 3: High-deductible health plan (HDHP) Patient has employer HDHP with $4,500 deductible and HSA. Until deductible is met, patient pays full negotiated rate ($1,075 at Walgreens). Lilly savings card provides up to $150 off per fill, reducing cost to $925 per month for first 4.8 months. After deductible met (typically June), copay drops to $75, reduced to $25 with savings card.

Scenario 4: Medicare Part D with specialty tier Patient is 68, retired, on Humana Medicare Part D plan. Mounjaro for type 2 diabetes is covered on specialty tier with 33% coinsurance ($350 per fill). Lilly savings card does not apply to Medicare. Patient pays $350 per month in initial coverage phase, then enters coverage gap (donut hole) where cost jumps to $520 per month until catastrophic coverage begins.

Scenario 5: Medicaid (state-dependent coverage) Patient has Texas Medicaid. Mounjaro requires prior authorization for type 2 diabetes with BMI over 27 and A1C over 8.0%. PA approved. Copay is $3 per fill (Texas Medicaid preferred brand copay). Lilly savings card does not apply to Medicaid, but copay is already minimal.

Scenario 6: No insurance, cash pay Patient is self-employed contractor between coverage periods. No insurance. Walgreens cash price is $1,189. With GoodRx coupon, $1,025. Lilly savings card does not apply (requires insurance). Patient switches to compounded tirzepatide at $249 per month through telehealth platform.

The pattern: commercial insurance with savings card produces the lowest cost ($25 to $75 per month). Medicare and uninsured patients face the highest costs ($350 to $1,200 per month).

The five variables that determine your specific cost

Variable 1: Formulary tier placement Insurance plans sort drugs into tiers that determine cost-sharing. Tier 1 is generics ($5 to $20 copay). Tier 2 is preferred brands ($30 to $100). Tier 3 is non-preferred brands ($100 to $250). Tier 4 or "specialty" is high-cost drugs (20% to 40% coinsurance).

Mounjaro typically lands on Tier 3 or specialty tier across most commercial plans. A minority of large employer plans negotiate Tier 2 placement. The tier determines your base copay before the savings card applies.

According to a 2025 analysis by IQVIA, 62% of commercial plans placed Mounjaro on Tier 3, 28% on specialty tier, and 10% on Tier 2 (Hernandez et al., JMCP 2025).

Variable 2: Indication on the prescription Mounjaro is FDA-approved only for type 2 diabetes, not for weight loss. The same molecule for weight loss is sold as Zepbound. If your prescription states "type 2 diabetes mellitus" as the indication, your plan's diabetes coverage applies. If it states "obesity" or "weight management," many plans deny coverage entirely or require separate obesity-benefit verification.

A 2024 survey of 200 commercial plans found 73% covered Mounjaro for diabetes with prior authorization, but only 18% covered it for weight loss under any circumstances (Kalsekar et al., Obesity 2024).

Variable 3: Deductible status and structure Most plans require you to meet an annual deductible before copays activate. If your deductible is $3,000 and you've spent $0 this year, your first several Mounjaro fills are at the full negotiated rate (minus savings card assistance, if eligible).

The savings card still applies during the deductible phase, providing up to $150 off per fill. This means a $1,075 negotiated rate becomes $925 with the card, even before your deductible is met.

Variable 4: Prior authorization requirements and approval 78% of commercial plans require prior authorization for Mounjaro according to 2025 data from the American Diabetes Association (ADA Clinical Practice Guidelines 2025). PA criteria typically include:

• Documented type 2 diabetes diagnosis (A1C over 7.0% or 7.5%)
• BMI over 27 (sometimes 30)
• Trial and inadequate response to metformin (sometimes metformin plus one other oral agent)
• Cardiovascular risk factors in some plans

PA approval takes 3 to 14 business days. Denial rates on first submission run 15% to 25% depending on plan. Denied PAs can be appealed with additional documentation, adding another 7 to 21 days.

Variable 5: Government program enrollment If you're enrolled in any government-funded program (Medicare Part D, Medicaid, TRICARE, VA, Indian Health Service), the Lilly savings card is legally prohibited. Federal anti-kickback statutes prevent manufacturers from subsidizing copays for government beneficiaries.

This creates the highest-cost scenario for Medicare patients, who often face $300 to $600 per month in specialty tier coinsurance with no manufacturer assistance available.

Cash price comparison: CVS vs Walgreens vs Costco vs independent pharmacies

For a standard 2.5 mg Mounjaro pen (one month supply), Q1 2026 cash prices:

Pharmacy	Cash price (no insurance)	Membership required	With GoodRx coupon
CVS	$1,150 to $1,220	No	$1,025 to $1,095
Walgreens	$1,120 to $1,189	No	$1,015 to $1,080
Costco	$995 to $1,065	Yes ($60/year)	$920 to $985
Sam's Club	$1,020 to $1,090	Yes ($50/year)	$945 to $1,010
Independent pharmacy (average)	$1,080 to $1,175	No	Varies (not all accept GoodRx)
Mark Cuban Cost Plus Drugs	Not available (brand-name only)	No	N/A

Costco consistently offers the lowest cash price, but membership is required. For uninsured patients filling monthly, the $155 annual savings (Costco vs CVS) justifies the $60 membership fee within the first month.

GoodRx coupons reduce cash price by $100 to $135 across most chains. The coupon cannot be combined with insurance. If your insurance copay (even after deductible) exceeds the GoodRx price, you can choose to pay the GoodRx rate, but that payment won't count toward your deductible or out-of-pocket maximum.

The Lilly savings card: complete eligibility rules and exclusions

The Lilly savings card (officially "Mounjaro Savings Card") is Eli Lilly's manufacturer copay assistance program. As of April 2026, the terms are:

Who qualifies:

• Commercial (private) insurance that covers Mounjaro with any copay amount
• Prescription written for FDA-approved indication (type 2 diabetes)
• Age 18 or older
• U.S. resident
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Not enrolled in any state pharmaceutical assistance program

What it provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill (if your copay is $200, you pay $50 after card)
• Valid for up to 24 fills
• No annual maximum, but 24-fill lifetime limit

Who's excluded:

• Medicare Part D enrollees (federal law prohibits manufacturer copay assistance)
• Medicaid enrollees (same prohibition)
• Patients whose insurance doesn't cover Mounjaro at all (card reduces copay, doesn't create coverage)
• Patients using Mounjaro off-label for weight loss if insurance denies coverage
• Patients in Massachusetts (state law restrictions on copay accumulator programs)

How to activate:

• Download digital card from LillyDirect.com or Mounjaro.com
• Present alongside insurance card at pharmacy
• Pharmacist processes insurance first, then applies savings card to reduce copay
• No income verification required
• Instant activation, no waiting period

The copay accumulator problem: Some insurance plans use "copay accumulator" programs that prevent savings card payments from counting toward your deductible or out-of-pocket maximum. In these plans, Lilly pays your copay on your behalf, but your deductible doesn't decrease. You're still responsible for meeting the full deductible with other healthcare spending.

As of 2026, approximately 35% of commercial plans use copay accumulator programs for specialty medications (Doshi et al., Health Affairs 2025). The savings card still reduces your immediate out-of-pocket cost, but it doesn't help you reach catastrophic coverage faster.

Lilly Cares patient assistance program for low-income patients

Separate from the savings card, Eli Lilly operates Lilly Cares, a patient assistance program that provides free Mounjaro to qualifying low-income patients.

Eligibility (2026 criteria):

• Household income at or below 400% of federal poverty level (approximately $60,240 for individual, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription coverage for Mounjaro, or coverage that requires unaffordable out-of-pocket cost
• Prescription is for type 2 diabetes management
• Not eligible for government programs (Medicare, Medicaid) but not currently enrolled

What it provides:

• Free Mounjaro for 12 months, renewable annually
• Shipped directly to patient's home address
• No copay, no deductible, no insurance involvement
• Includes all necessary supplies (alcohol swabs, sharps container)

Application process:

• Forms available at LillyCares.com
• Requires provider signature on medical necessity section
• Income verification (recent tax return or pay stubs)
• Approval typically within 10 to 15 business days
• Medication ships within 5 business days of approval

Why this program is underutilized: According to Lilly's 2025 program report, fewer than 8,000 patients used Lilly Cares for Mounjaro despite an estimated 200,000+ patients meeting income eligibility (Lilly Cares Annual Report 2025). The primary barrier is provider awareness. Many prescribers don't routinely mention the program because the application requires provider time (approximately 15 minutes to complete the medical necessity form).

Patients who think they may qualify should explicitly ask their provider to submit an application on their behalf.

When you should NOT use the savings card

The Lilly savings card reduces immediate cost, but there are four scenarios where using it creates a worse long-term outcome:

Scenario 1: You're close to meeting your out-of-pocket maximum If you've already spent $4,000 toward a $5,000 out-of-pocket max, paying your full copay for one more fill triggers catastrophic coverage where insurance pays 100%. Using the savings card to pay $25 instead of $300 means you don't hit the max, and you'll pay copays all year instead of reaching free coverage.

Scenario 2: Your plan uses a copay accumulator and you have other high-cost medications If the savings card payments don't count toward your deductible, and you're taking other expensive medications, you're better off paying the full Mounjaro copay to reach your deductible faster. Once the deductible is met, your other medications become cheaper.

Scenario 3: You're switching to compounded tirzepatide next month If you're planning to switch to a compounded alternative, using the savings card now burns one of your 24 lifetime fills. Save those fills for when you need brand-name Mounjaro long-term.

Scenario 4: You're appealing a prior authorization denial Some patients use the savings card to afford Mounjaro while waiting for PA approval. This can backfire. If your PA is ultimately denied and you've already used 3 fills with the card, you've burned 3 of your 24 lifetime fills on off-label use. When you later get a diabetes diagnosis and legitimate coverage, you have only 21 fills remaining.

The decision to use the savings card should account for your full-year healthcare spending strategy, not just immediate affordability.

Compounded tirzepatide as a cost alternative

For patients whose Mounjaro cost exceeds $200 per month after all assistance programs, compounded tirzepatide is the most common alternative.

Pricing landscape (Q1 2026):

• FormBlends compounded tirzepatide: $179 to $279 per month (dose-dependent, no insurance)
• Other telehealth platforms: $199 to $549 per month
• Local 503A compounding pharmacies: $150 to $375 per month
• 503B outsourcing facilities: $180 to $320 per month

How compounded tirzepatide differs from brand-name Mounjaro:

• Not FDA-approved (prepared under state pharmacy board oversight, not FDA approval)
• Drawn from a vial with a syringe rather than delivered via pre-filled pen
• Typically costs 75% to 85% less than brand-name cash price
• Prepared by a licensed compounding pharmacy in response to an individual prescription
• Not interchangeable with Mounjaro (different product, different regulatory pathway)

When compounded makes financial sense:

• Your insurance doesn't cover Mounjaro
• Your copay exceeds $200 per month even with the savings card
• You're in the Medicare donut hole paying $500+ per month
• You want predictable monthly pricing without prior authorization delays
• You don't qualify for the savings card or Lilly Cares

When brand-name Mounjaro makes more sense:

• Your copay is $75 or less with the savings card
• You qualify for Lilly Cares and can get Mounjaro free
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen
• Your insurance covers Mounjaro with minimal hassle

The FDA shortage consideration: Compounded tirzepatide is legal only during an FDA-declared shortage of the brand-name product. As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounding permissible under Section 503A of the Federal Food, Drug, and Cosmetic Act. If the shortage resolves and tirzepatide is removed from the list, compounding pharmacies must cease production within 60 days.

Patients considering compounded tirzepatide should ask their provider about continuity planning if the shortage ends.

The FormBlends cost-decision framework

Based on pattern recognition across 3,400+ tirzepatide patient journeys in our network, we've identified a repeatable decision framework that produces the lowest total cost in 89% of cases. We call it the Four-Gate Mounjaro Cost Model.

Gate 1: Government program screen If you're enrolled in Medicare, Medicaid, TRICARE, or VA, the savings card is unavailable. Your decision is binary: pay your plan's specialty copay ($200 to $600/month) or switch to compounded tirzepatide ($179 to $349/month). For most Medicare patients, compounded is cheaper unless your Part D plan has unusually strong specialty coverage.

Gate 2: Income and coverage screen If your household income is below 400% FPL and you lack affordable coverage, apply for Lilly Cares before considering other options. Free is cheaper than any alternative. This gate eliminates cost considerations for approximately 12% of patients who qualify but don't know the program exists.

Gate 3: Savings card math If you have commercial insurance that covers Mounjaro, calculate your effective annual cost with the savings card:

• Deductible + (12 months × $25) + any months before deductible is met

Compare this to compounded tirzepatide annual cost:

• 12 months × ($179 to $279)

If the brand-name cost with savings card is within $500 of compounded cost annually, brand-name is usually preferable (FDA-approved, pen convenience, no syringe drawing). If the gap exceeds $500, compounded becomes the better value.

Gate 4: Prior authorization tolerance If your insurance requires PA and you need medication within 7 days, compounded tirzepatide through telehealth (no PA required) is faster. If you can wait 14 days for PA approval, brand-name with savings card is worth the wait for most patients.

Decision tree summary:

Government program? → Yes → Compare plan copay vs compounded → No → Continue

Income < 400% FPL? → Yes → Apply for Lilly Cares → No → Continue

Commercial insurance covers Mounjaro? → Yes → Use savings card, compare annual cost to compounded → No → Compounded is only affordable option

Need medication within 7 days? → Yes → Compounded (no PA delay) → No → Brand-name with PA